Nintedanib

Nintedanib (Vargatef, Boehringer Ingelheim International GmbH) has 1 EU-approved indication in 1 tumour type.
Approved indications of Nintedanib
Biomarker requirementRegimenSettingConditions
Non-small cell lung cancer1
None
+ docetaxel
2L
advanced
Adenocarcinoma only; After first-line chemotherapy
Full text of section 4.1 (therapeutic indications)

Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Label history

30 changes to the Vargatef label since 2016, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes